Skip to main content
Premium Trial:

Request an Annual Quote

Cenix Extends RNAi-based Target Validation Project with CellCentric

NEW YORK (GenomeWeb News) – RNAi services firm Cenix BioScience said today that it has extended an existing collaboration with CellCentric to validate epigenetic oncology drug candidates.
 
The new project follows a pilot study that the companies began in March under which Cenix used its RNAi-based phenotypic characterization platform to study several of CellCentric’s drug target candidates in a diverse panel of human cell lines.
 
Under the expanded agreement, Cenix said it will use the same RNAi platform, along with proprietary high-content assays and Definiens’ Cellenger image analysis software, to analyze loss-of-function phenotypes for “several more” oncology target candidates across a new collection of human cell lines.
 
Further details of the collaboration were not disclosed.
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.